Izervay (Avacincaptad PEGol Sodium/PF) Patent Expiration, LOE Window & CMS Spending

Izervay (Avacincaptad PEGol Sodium/PF) by Astellas Pharma: Off-Patent Genericized (AB Competition), 0 AB generics, $6.3M 2024 CMS Part D & Medicaid spend, and $2,100 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$6.3M
2024 Medicare Part D Spend$3.9M
2024 Medicaid Spend$2.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,100 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.